CN118489901A - Nano-ultra-micro emulsification process and products prepared by the process - Google Patents
Nano-ultra-micro emulsification process and products prepared by the process Download PDFInfo
- Publication number
- CN118489901A CN118489901A CN202410964180.9A CN202410964180A CN118489901A CN 118489901 A CN118489901 A CN 118489901A CN 202410964180 A CN202410964180 A CN 202410964180A CN 118489901 A CN118489901 A CN 118489901A
- Authority
- CN
- China
- Prior art keywords
- calcium
- mixture
- parts
- nano
- emulsifier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004945 emulsification Methods 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 24
- 230000008569 process Effects 0.000 title claims abstract description 17
- 102000008186 Collagen Human genes 0.000 claims abstract description 69
- 108010035532 Collagen Proteins 0.000 claims abstract description 69
- 229920001436 collagen Polymers 0.000 claims abstract description 69
- 239000000203 mixture Substances 0.000 claims abstract description 56
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 51
- 235000018102 proteins Nutrition 0.000 claims abstract description 30
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 29
- 241000157862 Dicamptodontidae Species 0.000 claims abstract description 25
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 23
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 23
- 235000021119 whey protein Nutrition 0.000 claims abstract description 23
- 241000251468 Actinopterygii Species 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 19
- 238000010008 shearing Methods 0.000 claims abstract description 18
- 239000002131 composite material Substances 0.000 claims abstract description 16
- 238000003756 stirring Methods 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 11
- 239000000796 flavoring agent Substances 0.000 claims abstract description 10
- 239000002562 thickening agent Substances 0.000 claims abstract description 9
- 235000013355 food flavoring agent Nutrition 0.000 claims abstract description 8
- 239000000654 additive Substances 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 230000001954 sterilising effect Effects 0.000 claims abstract description 5
- 238000001816 cooling Methods 0.000 claims abstract 2
- 239000012467 final product Substances 0.000 claims abstract 2
- 238000000265 homogenisation Methods 0.000 claims description 33
- 239000003607 modifier Substances 0.000 claims description 33
- 239000000839 emulsion Substances 0.000 claims description 22
- 210000000988 bone and bone Anatomy 0.000 claims description 21
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 19
- 239000011575 calcium Substances 0.000 claims description 19
- 229960005069 calcium Drugs 0.000 claims description 19
- 229910052791 calcium Inorganic materials 0.000 claims description 19
- 235000001465 calcium Nutrition 0.000 claims description 19
- 229930003316 Vitamin D Natural products 0.000 claims description 17
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 17
- 235000019166 vitamin D Nutrition 0.000 claims description 17
- 239000011710 vitamin D Substances 0.000 claims description 17
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 17
- 229940046008 vitamin d Drugs 0.000 claims description 17
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 14
- 235000020166 milkshake Nutrition 0.000 claims description 14
- 235000010489 acacia gum Nutrition 0.000 claims description 12
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 12
- 230000001804 emulsifying effect Effects 0.000 claims description 12
- 239000000194 fatty acid Substances 0.000 claims description 12
- 229930195729 fatty acid Natural products 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 12
- 235000013804 distarch phosphate Nutrition 0.000 claims description 11
- 239000001245 distarch phosphate Substances 0.000 claims description 11
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 claims description 10
- 229940080313 sodium starch Drugs 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 8
- 239000004375 Dextrin Substances 0.000 claims description 8
- 235000019425 dextrin Nutrition 0.000 claims description 8
- 229920001100 Polydextrose Polymers 0.000 claims description 7
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 7
- 239000001354 calcium citrate Substances 0.000 claims description 7
- 235000013856 polydextrose Nutrition 0.000 claims description 7
- 239000001259 polydextrose Substances 0.000 claims description 7
- 229940035035 polydextrose Drugs 0.000 claims description 7
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 7
- -1 lactose oligosaccharide Chemical class 0.000 claims description 5
- 229920001817 Agar Polymers 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 229920001202 Inulin Polymers 0.000 claims description 3
- 229920002774 Maltodextrin Polymers 0.000 claims description 3
- 239000005913 Maltodextrin Substances 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- 229940035034 maltodextrin Drugs 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 229960003563 calcium carbonate Drugs 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 229960002713 calcium chloride Drugs 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- 229960004256 calcium citrate Drugs 0.000 claims description 2
- 239000004227 calcium gluconate Substances 0.000 claims description 2
- 229960004494 calcium gluconate Drugs 0.000 claims description 2
- 235000013927 calcium gluconate Nutrition 0.000 claims description 2
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims description 2
- 229940095618 calcium glycerophosphate Drugs 0.000 claims description 2
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 2
- 229940087373 calcium oxide Drugs 0.000 claims description 2
- 235000012255 calcium oxide Nutrition 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- MKJXYGKVIBWPFZ-CEOVSRFSSA-L calcium;(2s)-2-hydroxypropanoate Chemical compound [Ca+2].C[C@H](O)C([O-])=O.C[C@H](O)C([O-])=O MKJXYGKVIBWPFZ-CEOVSRFSSA-L 0.000 claims description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229940095672 calcium sulfate Drugs 0.000 claims 1
- 235000011132 calcium sulphate Nutrition 0.000 claims 1
- 238000007599 discharging Methods 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000047 product Substances 0.000 abstract description 17
- 235000013305 food Nutrition 0.000 abstract description 6
- 239000013589 supplement Substances 0.000 abstract description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 4
- 239000011707 mineral Substances 0.000 abstract description 4
- 235000010755 mineral Nutrition 0.000 abstract description 4
- 235000015097 nutrients Nutrition 0.000 abstract description 4
- 238000001338 self-assembly Methods 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract description 3
- 229930003231 vitamin Natural products 0.000 abstract description 3
- 235000013343 vitamin Nutrition 0.000 abstract description 3
- 239000011782 vitamin Substances 0.000 abstract description 3
- 238000004090 dissolution Methods 0.000 abstract description 2
- 235000012041 food component Nutrition 0.000 abstract description 2
- 239000004530 micro-emulsion Substances 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 239000007908 nanoemulsion Substances 0.000 description 11
- 244000215068 Acacia senegal Species 0.000 description 10
- 229920000084 Gum arabic Polymers 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 10
- 239000000205 acacia gum Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 235000012054 meals Nutrition 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 230000032258 transport Effects 0.000 description 8
- 230000004580 weight loss Effects 0.000 description 8
- 229940057917 medium chain triglycerides Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 230000032895 transmembrane transport Effects 0.000 description 6
- 229920001285 xanthan gum Polymers 0.000 description 6
- 235000010493 xanthan gum Nutrition 0.000 description 6
- 239000000230 xanthan gum Substances 0.000 description 6
- 229940082509 xanthan gum Drugs 0.000 description 6
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 5
- 239000004386 Erythritol Substances 0.000 description 5
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 235000019414 erythritol Nutrition 0.000 description 5
- 229940009714 erythritol Drugs 0.000 description 5
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000001630 malic acid Substances 0.000 description 5
- 235000011090 malic acid Nutrition 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000037208 balanced nutrition Effects 0.000 description 2
- 235000019046 balanced nutrition Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- XDLYMKFUPYZCMA-UHFFFAOYSA-M sodium;4-oct-1-enoxy-4-oxobutanoate Chemical compound [Na+].CCCCCCC=COC(=O)CCC([O-])=O XDLYMKFUPYZCMA-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000012762 dietary quality Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000019823 konjac gum Nutrition 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000021486 meal replacement product Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
- A23L2/62—Clouding agents; Agents to improve the cloud-stability
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
技术领域Technical Field
本发明属于食品组合物技术领域,具体涉及一种纳米超微乳化工艺及其采用该工艺制备的产品。The invention belongs to the technical field of food compositions, and in particular relates to a nano-ultramicro emulsification process and a product prepared by the process.
背景技术Background Art
肥胖的发生与遗传因素、社会环境因素、心理因素等多种因素有关,但是其发生的直接原因是摄取的能量多余消耗的能量,使得多余的能量以脂肪的形式储存起来从而造成肥胖。目前,市场上减肥物品包括减肥药和减肥保健食品,减肥药虽具有较明显的减肥效果,但是存在副作用大,药物依赖性强的缺点,停止服用后容易反弹。而减肥保健食品虽具有较小的副作用和依赖性,但是减肥效果不明显。The occurrence of obesity is related to genetic factors, social environmental factors, psychological factors and other factors, but the direct cause of its occurrence is that the energy intake exceeds the energy consumed, so that the excess energy is stored in the form of fat, thus causing obesity. At present, weight loss products on the market include weight loss pills and weight loss health foods. Although weight loss pills have obvious weight loss effects, they have the disadvantages of large side effects and strong drug dependence, and are prone to rebound after stopping taking them. Although weight loss health foods have less side effects and dependence, the weight loss effect is not obvious.
在这样的大背景下,代餐食品在市场上应运而出。近几年,市场上的代餐奶昔受到消费者的广大追捧。代餐蛋白粉是一种可以替代或减少正常膳食的食物,旨在提供营养均衡和控制热量的摄入。代餐粉通常是由各种营养成分和纤维素的混合物,经过加工后制成的粉未状食品。由于其方便、快捷、低热量等特点,受到广泛欢迎。中国专利CN102687750B公开了一种减肥代餐蛋白型固体饮料,由以下重量百分比的原料制成:浓缩乳清蛋白粉、大豆分离蛋白粉,脱脂乳粉、水溶性膳食纤维、麦芽糊精、大豆卵磷脂、甜味剂、复合维生素、矿物质等,主要突出营养均衡,不会对人体造成伤害;中国专利CN113349262A公开了一种蛋白代餐粉及其制备方法,包括大豆蛋白粉、速溶脱脂乳粉、抗性糊精、圆苞车前子壳、菊粉、草莓味香精、七水硫酸镁、水苏糖等,突出产品营养物质混合均匀、易吸收,冲泡状态好及豆腥味小、风味好的蛋白代餐粉。但是随着消费者对于饮食质量要求的不断提高,更加便利、吸收率更高、代餐系效果更好的奶昔会更加符合消费者的要求,但是现有技术中提供的蛋白代餐食品均存在蛋白吸收不好、溶解性不好、口感不够细腻等不足。In this context, meal replacement foods have emerged in the market. In recent years, meal replacement shakes on the market have been widely sought after by consumers. Meal replacement protein powder is a food that can replace or reduce normal meals, aiming to provide nutritional balance and control calorie intake. Meal replacement powder is usually a mixture of various nutrients and cellulose, processed into a powdered food. Due to its convenience, speed, and low calories, it is widely welcomed. Chinese patent CN102687750B discloses a protein-based solid beverage for weight loss meal replacement, which is made of the following raw materials in percentage by weight: concentrated whey protein powder, soy protein isolate powder, skim milk powder, water-soluble dietary fiber, maltodextrin, soy lecithin, sweetener, multivitamin, minerals, etc., mainly highlighting balanced nutrition and not causing harm to the human body; Chinese patent CN113349262A discloses a protein meal replacement powder and a preparation method thereof, including soy protein powder, instant skim milk powder, resistant dextrin, round-shell psyllium husk, inulin, strawberry flavor essence, magnesium sulfate heptahydrate, stachyose, etc., highlighting that the product nutrients are evenly mixed, easy to absorb, and the brewing state is good, and the beany smell is small and the flavor is good. However, with the continuous improvement of consumers' requirements for dietary quality, milkshakes that are more convenient, have higher absorption rates, and have better meal replacement effects will better meet the requirements of consumers, but the protein meal replacement foods provided in the prior art all have shortcomings such as poor protein absorption, poor solubility, and insufficiently delicate taste.
因此需要开发一种溶解性好、营养更加均衡、吸收好的产品,为现有的代餐产品体系提供新的更优选择。Therefore, it is necessary to develop a product with good solubility, more balanced nutrition and good absorption to provide a new and better choice for the existing meal replacement product system.
发明内容Summary of the invention
针对现有技术中存在的不足,本发明旨在以深海鱼胶原蛋白、骨胶原蛋白、乳清蛋白、大鲵胶原蛋白肽、大鲵维生素、矿物质等为活性营养组分,加入复合乳化剂,利用纳米超微乳液自组装技术,制备得到吸收性好、溶解速度快、口感细腻,同时能够补充多种蛋白和营养素的高品质奶昔产品。In view of the deficiencies in the prior art, the present invention aims to use deep-sea fish collagen, bone collagen, whey protein, giant salamander collagen peptides, giant salamander vitamins, minerals, etc. as active nutritional components, add a composite emulsifier, and utilize nano-ultrafine emulsion self-assembly technology to prepare a high-quality milkshake product with good absorbability, fast dissolution speed, and delicate taste, while being able to supplement a variety of proteins and nutrients.
为了实现上述目的,本发明采用如下技术方案实现:In order to achieve the above object, the present invention adopts the following technical solutions:
一方面,本发明提供了一种纳米超微乳化工艺,具体步骤如下:On the one hand, the present invention provides a nano-ultramicro emulsification process, the specific steps are as follows:
(1)将复合蛋白粉加入90-95℃热水中,充分溶解后得到第一混合物,备用;(1) Add the composite protein powder into hot water at 90-95°C and fully dissolve to obtain a first mixture for later use;
(2)向步骤(1)得到的第一混合物中加入膳食纤维、添加剂、增稠剂和调味剂,充分搅拌至溶液呈均一状,得到第二混合物;(2) adding dietary fiber, additives, thickeners and flavoring agents to the first mixture obtained in step (1), and stirring thoroughly until the solution becomes uniform, to obtain a second mixture;
(3)将复合乳化剂加入95-100℃热水中,搅拌0.5-2h,使溶解分散均匀,得到溶液;(3) Add the composite emulsifier into 95-100°C hot water and stir for 0.5-2h to dissolve and disperse evenly to obtain a solution;
(4)将步骤(2)得到的第二混合物和步骤(3)得到的溶液混合,利用高速分散机进行高速剪切,得到预均质乳液;(4) mixing the second mixture obtained in step (2) and the solution obtained in step (3), and performing high-speed shearing using a high-speed disperser to obtain a pre-homogenized emulsion;
(5)将预均质乳液进行高压均质处理,得到均质乳液,对其进行灭菌、降温,即得到产品。(5) The pre-homogenized emulsion is subjected to high-pressure homogenization to obtain a homogenized emulsion, which is then sterilized and cooled to obtain the product.
其中,in,
步骤(1)中所述的复合蛋白粉包括鱼胶原蛋白、骨胶原蛋白、乳清蛋白和大鲵胶原蛋白肽中的一种或多种;The compound protein powder in step (1) comprises one or more of fish collagen, bone collagen, whey protein and giant salamander collagen peptide;
优选地,所述的复合蛋白粉为鱼胶原蛋白、骨胶原蛋白、乳清蛋白和大鲵胶原蛋白肽的混合物;按重量份数计为:鱼胶原蛋白5-50份、骨胶原蛋白1-20份、乳清蛋白0.5-20份、大鲵胶原蛋白肽0.005-0.1份;Preferably, the composite protein powder is a mixture of fish collagen, bone collagen, whey protein and giant salamander collagen peptide; the weight proportions are: 5-50 parts of fish collagen, 1-20 parts of bone collagen, 0.5-20 parts of whey protein, and 0.005-0.1 parts of giant salamander collagen peptide;
优选地,按重量份数计为:鱼胶原蛋白10-40份、骨胶原蛋白5-15份、乳清蛋白5-15份、大鲵胶原蛋白肽0.05-0.1份;Preferably, the components are as follows: 10-40 parts of fish collagen, 5-15 parts of bone collagen, 5-15 parts of whey protein, and 0.05-0.1 parts of giant salamander collagen peptide;
再优选地,按重量份数计为:鱼胶原蛋白20-30份、骨胶原蛋白8-12份、乳清蛋白8-12份、大鲵胶原蛋白肽0.08-0.1份。More preferably, the ingredients are as follows, by weight: 20-30 parts of fish collagen, 8-12 parts of bone collagen, 8-12 parts of whey protein, and 0.08-0.1 parts of giant salamander collagen peptide.
步骤(2)中所述的膳食纤维选自聚葡萄糖、抗性糊精、菊粉、低聚果糖、低聚异麦芽糖、低聚乳糖、低聚木糖、大豆低聚糖、琼脂粉、羧甲基纤维素和果胶中的一种或几种;按重量份数为50-100份;优选为60-90份;再优选为70-80份。The dietary fiber described in step (2) is selected from one or more of polydextrose, resistant dextrin, inulin, fructo-oligosaccharide, isomaltooligosaccharide, lacto-oligosaccharide, xylo-oligosaccharide, soybean oligosaccharide, agar powder, carboxymethyl cellulose and pectin; the weight proportion is 50-100 parts; preferably 60-90 parts; more preferably 70-80 parts.
优选地,所述的膳食纤维为聚葡萄糖和抗性糊精的混合物;两者质量比为1:1。Preferably, the dietary fiber is a mixture of polydextrose and resistant dextrin; the mass ratio of the two is 1:1.
步骤(2)中所述的添加剂为维生素D和钙,所述的钙的来源包括碳酸钙、葡萄糖酸钙、柠檬酸钙、L-乳酸钙、磷酸氢钙、氯化钙、磷酸三钙、甘油磷酸钙、氧化钙或/和硫酸钙,优选为柠檬酸钙;按重量份数计为:维生素D 0.000001份、钙0.01-0.8份;The additives in step (2) are vitamin D and calcium, and the source of calcium includes calcium carbonate, calcium gluconate, calcium citrate, calcium L-lactate, calcium hydrogen phosphate, calcium chloride, tricalcium phosphate, calcium glycerophosphate, calcium oxide or/and calcium sulfate, preferably calcium citrate; by weight: 0.000001 part of vitamin D and 0.01-0.8 part of calcium;
优选地,按重量份数计为:维生素D 0.000001份、钙0.1-0.6份;Preferably, by weight: 0.000001 part of vitamin D, 0.1-0.6 part of calcium;
再优选地,按重量份数计为:维生素D 0.000001份、钙0.2-0.5份。More preferably, the components are calculated by weight: 0.000001 part of vitamin D and 0.2-0.5 part of calcium.
步骤(2)中所述的增稠剂选自果胶、黄原胶、阿拉伯胶、卡拉胶、魔芋胶和羧甲基纤维素钠中的一种或几种;按重量份数计为0.1-2份;优选为0.5-1.5份;再优选为0.8-1.2份。The thickener in step (2) is selected from one or more of pectin, xanthan gum, gum arabic, carrageenan, konjac gum and sodium carboxymethyl cellulose; the weight portion is 0.1-2 parts; preferably 0.5-1.5 parts; more preferably 0.8-1.2 parts.
优选地,所述的增稠剂为黄原胶。Preferably, the thickener is xanthan gum.
步骤(3)中所述的复合乳化剂包括乳化剂和乳化改性剂;The composite emulsifier described in step (3) includes an emulsifier and an emulsification modifier;
作为一些优选地实施方案,所述的乳化剂与乳化改性剂的质量比为8-12:1;优选为9-10:1。As some preferred embodiments, the mass ratio of the emulsifier to the emulsification modifier is 8-12:1; preferably 9-10:1.
所述的乳化剂选自单,双甘油脂肪酸酯、辛烯基琥珀酸淀粉钠、羟丙基甲基纤维素、麦芽糊精和琼脂中的一种或几种;按重量份数计为5-10份;The emulsifier is selected from one or more of mono- and di-glycerol fatty acid esters, sodium octenyl succinate starch, hydroxypropyl methylcellulose, maltodextrin and agar; the amount is 5-10 parts by weight;
优选地,所述的乳化剂为单,双甘油脂肪酸酯、辛烯基琥珀酸淀粉钠和羟丙基甲基纤维素的混合物;Preferably, the emulsifier is a mixture of mono- and di-glycerol fatty acid esters, sodium starch octenylsuccinate and hydroxypropyl methylcellulose;
再优选地,所述的单,双甘油脂肪酸酯、辛烯基琥珀酸淀粉钠和羟丙基甲基纤维素的质量比为1-2:3-5:1;优选为1:3:1。More preferably, the mass ratio of the mono- and di-glycerol fatty acid esters, sodium starch octenylsuccinate and hydroxypropyl methylcellulose is 1-2:3-5:1; preferably 1:3:1.
所述的乳化改性剂为阿拉伯胶、中链甘油三酯和乙酰化二淀粉磷酸酯的混合物,其质量比为1-3:1:1;优选为2:1:1。The emulsifying modifier is a mixture of gum arabic, medium-chain triglycerides and acetylated distarch phosphate, with a mass ratio of 1-3:1:1, preferably 2:1:1.
步骤(4)中所述的调味剂选自柠檬酸、苹果酸、柠檬酸钠、柠檬酸钾、三氯蔗糖、甜菊糖苷、罗汉果甜苷、木糖醇、麦芽糖醇、赤藓糖醇、乳糖醇和山梨糖醇中的一种或几种;按重量份数计为50-80份。The flavoring agent described in step (4) is selected from one or more of citric acid, malic acid, sodium citrate, potassium citrate, sucralose, steviol glycosides, mogroside, xylitol, maltitol, erythritol, lactitol and sorbitol; the amount is 50-80 parts by weight.
步骤(4)中所述的高速剪切得转速为12000-15000rpm/min,剪切时间15-20min;The high-speed shearing in step (4) has a rotation speed of 12000-15000 rpm/min and a shearing time of 15-20 min;
步骤(5)所述的均质的具体操作为:均质前进料温度控制在60℃以下,出料温度为70℃以下,均质压力25-120Mpa,循环均质1-3次。The specific operation of the homogenization in step (5) is as follows: the feed temperature before homogenization is controlled below 60°C, the discharge temperature is below 70°C, the homogenization pressure is 25-120Mpa, and the homogenization is circulated 1-3 times.
步骤(5)所述的灭菌温度为80-95℃,时间为30-50min;所述的产品为奶昔组合物。The sterilization temperature in step (5) is 80-95° C. and the time is 30-50 min; the product is a milkshake composition.
本发明所述的奶昔组合物采用四种蛋白组合:The milkshake composition of the present invention uses a combination of four proteins:
乳清蛋白是牛奶中天然存在的一类可溶蛋白,具有高生物价、高效化率、高蛋白质功效比和高利用率,是公认的人体优质蛋白质补充剂。浓缩乳清蛋白属于快蛋白,相对分子量小,易吸收;也是天然的全蛋白,含有人体所需的所有必需氨基酸;同时富含支链氨基酸(特别是亮氨酸),促进肌肉生长、富含半胱氨酸,抗氧化。有益于健康的生物活性还包括乳清蛋白中的α-乳白蛋白、β-乳球蛋白、牛血清白蛋白、免疫球蛋白、乳铁蛋白和乳过氧化物酶,均具有不同的生物学活性。Whey protein is a type of soluble protein naturally found in milk. It has high biological value, high efficiency, high protein efficacy ratio and high utilization rate. It is recognized as a high-quality protein supplement for the human body. Concentrated whey protein is a fast-acting protein with a small molecular weight and is easily absorbed. It is also a natural complete protein that contains all the essential amino acids needed by the human body. It is also rich in branched-chain amino acids (especially leucine), which promotes muscle growth, is rich in cysteine, and is antioxidant. Other biological activities that are beneficial to health include α-lactalbumin, β-lactoglobulin, bovine serum albumin, immunoglobulin, lactoferrin and lactoperoxidase in whey protein, all of which have different biological activities.
胶原蛋白(也称胶原)是细胞外基质的一种结构蛋白质,约占胶原纤维固体物的85%。胶原蛋白是动物体中普遍存在的一种大分子蛋白,主要存在于动物的结缔组织(骨、软骨、皮肤、腱、韧等)中,占哺乳动物体内蛋白质的25%-30%,相当于体重的6%。胶原肽被肠腔内壁绒毛吸收进入血液的速度很快,小肽(尤其是二肽、三肽)的吸收率明显高于游离氨基肽,蛋白肽可被直接吸收而且比整蛋白的吸收率高很多。胶原蛋白具有很多对人体有益的作用,如抗骨质疏松、抗衰老、抗氧化、促进皮肤修复、抗血糖等诸多功能。本发明采用不同来源胶原蛋白组合,结合骨胶原蛋白和鱼胶原蛋白双重组合,全方面的补充人体所需,提高健康益处。大鲵胶原蛋白肽是通过绿色酶解技术从大鲵蛋白中提取、制备的活性肽。文献记载大鲵活性肽具有抗氧化、抗衰老、肝脏损伤保护、提高免疫力作用。Collagen (also known as collagen) is a structural protein of the extracellular matrix, accounting for about 85% of the solid matter of collagen fibers. Collagen is a macromolecular protein commonly found in animals, mainly in the connective tissues (bone, cartilage, skin, tendon, tenacious, etc.) of animals, accounting for 25%-30% of the protein in mammals, equivalent to 6% of body weight. Collagen peptides are absorbed into the blood very quickly by the villi on the inner wall of the intestinal cavity. The absorption rate of small peptides (especially dipeptides and tripeptides) is significantly higher than that of free amino peptides. Protein peptides can be directly absorbed and the absorption rate is much higher than that of whole proteins. Collagen has many beneficial effects on the human body, such as anti-osteoporosis, anti-aging, anti-oxidation, skin repair promotion, anti-glycemia and many other functions. The present invention adopts a combination of collagen from different sources, combined with a double combination of bone collagen and fish collagen, to fully supplement the needs of the human body and improve health benefits. Giant salamander collagen peptide is an active peptide extracted and prepared from giant salamander protein by green enzymatic hydrolysis technology. Literature records that giant salamander active peptides have antioxidant, anti-aging, liver damage protection and immunity enhancement effects.
此外,本发明还额外添加了维生素D与钙的黄金组合。随着生理年龄的增加,人体中钙元素不断在流失,特别是在35岁以后钙损失和钙形成的比例达到高峰,带来身体的负面影响包括骨质疏松、骨密度降低、骨骼强度降低等,因此保持适当的钙摄入对于维持骨骼健康、肌肉功能至关重要,而维生素D可以促进钙的吸收,提高机体对于肠道中钙离子的吸收,从而预防缺钙引起的骨质疏松症。In addition, the present invention also adds a golden combination of vitamin D and calcium. With the increase of physiological age, the calcium element in the human body is constantly lost, especially after the age of 35, the ratio of calcium loss to calcium formation reaches a peak, bringing negative effects on the body including osteoporosis, reduced bone density, reduced bone strength, etc. Therefore, maintaining proper calcium intake is crucial to maintaining bone health and muscle function, and vitamin D can promote calcium absorption and improve the body's absorption of calcium ions in the intestine, thereby preventing osteoporosis caused by calcium deficiency.
与现有技术相比,本申请的有益效果在于:Compared with the prior art, the beneficial effects of this application are:
(1)本发明创新应用纳米超微乳液自组装技术制备液体奶昔,使产品粒径达到纳米级,使蛋白的吸收量和吸收率都得到了明显提高;本发明以单,双甘油脂肪酸酯、辛烯基琥珀酸淀粉钠和羟丙基甲基纤维素的混合物作为乳化剂,并以阿拉伯胶、中链甘油三酯和乙酰化二淀粉磷酸酯的混合物作为乳化改性剂,并控制三者的质量比为1-3:1:1,采用该复合乳化剂能够使纳米超微乳液在体系中具有良好的稳定性,长期放置不会结团,分层;同时,该技术还可以提升产品口感、使其更加细腻。(1) The present invention innovatively applies nano-ultrafine emulsion self-assembly technology to prepare liquid milk shakes, so that the product particle size reaches the nano level, and the absorption amount and absorption rate of protein are significantly improved; the present invention uses a mixture of mono- and di-glycerol fatty acid esters, sodium starch octenyl succinate and hydroxypropyl methylcellulose as an emulsifier, and a mixture of gum arabic, medium-chain triglycerides and acetylated distarch phosphate as an emulsifying modifier, and controls the mass ratio of the three to be 1-3:1:1. The use of the composite emulsifier can make the nano-ultrafine emulsion have good stability in the system, and will not clump or stratify when placed for a long time; at the same time, the technology can also improve the taste of the product and make it more delicate.
(2)本发明通过控制剪切的转速以及均质的压力使得到的纳米乳液产品粒径更均匀,稳定性更高;(2) The present invention controls the shearing speed and homogenization pressure to make the obtained nanoemulsion product particle size more uniform and more stable;
(3)本发明提供的四重蛋白+维生素和矿物质组合,能够极大的发挥组合所带来的健康效果,补充人体各种蛋白所需,同时通过钙和维生素D的黄金组合,补充人体日常钙的吸收。(3) The quadruple protein + vitamin and mineral combination provided by the present invention can greatly exert the health effects brought by the combination, supplement the human body's need for various proteins, and at the same time supplement the human body's daily calcium absorption through the golden combination of calcium and vitamin D.
具体实施方式DETAILED DESCRIPTION
本发明中提到的上述特征,或实施例提到的特征可以任意组合。本案说明书所解释的所有特征可与任意方法形式并用,说明书中揭示的各个特征,可被任何可提供相同、均等或相似目的的取代性特征取代。因此除有特殊说明,所揭示的特征仅为均等或相似特征的一般性例子。The above features mentioned in the present invention or the features mentioned in the embodiments can be combined in any way. All the features explained in the specification of this case can be used in combination with any method form, and each feature disclosed in the specification can be replaced by any alternative feature that can provide the same, equal or similar purpose. Therefore, unless otherwise specified, the disclosed features are only general examples of equal or similar features.
下面结合具体实施例,进一步阐述本发明。这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中为注明具体条件的实施方法,通常按照常规条件或按照制造厂商所建议的条件。除非特殊说明,否则所有的百分比和分数按重量计。The present invention will be further described below in conjunction with specific examples. These examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In the following examples, the implementation methods for specifying specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise specified, all percentages and fractions are by weight.
除非另行定义,文中所使用的所有专业与科学用语与本领域技术人员所熟知的意义相同。此外,任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的优选实施方法与材料仅做示范作用。Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those known to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.
本发明所使用的原料均为普通市售产品。The raw materials used in the present invention are all common commercially available products.
鱼胶原蛋白购自湖北瑞邦生物科技有限公司公司,产品名称为鱼胶原蛋白肽;骨胶原蛋白购自包头东宝生物技术股份有限公司公司,产品名称为骨胶原蛋白肽粉(4A);乳清蛋白购自Volac International Ltd公司,型号为Volactive® Pro;大鲵胶原蛋白肽购自湖北瑞邦生物科技有限公司公司,产品名称:大鲵胶原蛋白肽粉。Fish collagen was purchased from Hubei Ruibang Biotechnology Co., Ltd., and the product name is fish collagen peptide; bone collagen was purchased from Baotou Dongbao Biotechnology Co., Ltd., and the product name is bone collagen peptide powder (4A); whey protein was purchased from Volac International Ltd, model Volactive® Pro; giant salamander collagen peptide was purchased from Hubei Ruibang Biotechnology Co., Ltd., and the product name is giant salamander collagen peptide powder.
实施例1一种奶昔组合物及其制备方法Example 1 A milkshake composition and preparation method thereof
按重量份数计包括如下组分:The components include the following by weight:
鱼胶原蛋白50份、骨胶原蛋白1份、乳清蛋白20份、大鲵胶原蛋白肽0.005份、维生素D 0.000001份、柠檬酸钙0.8份、乳化剂8.8份(单,双甘油脂肪酸酯、辛烯基琥珀酸淀粉钠和羟丙基甲基纤维素的质量比为2:5:1)、乳化改性剂1.1份(阿拉伯胶、中链甘油三酯和乙酰化二淀粉磷酸酯的质量比为2:1:1)、聚葡萄糖25份、抗性糊精25份、苹果酸10份、柠檬酸5份、赤藓糖醇35份、黄原胶1.0份。50 parts of fish collagen, 1 part of bone collagen, 20 parts of whey protein, 0.005 parts of giant salamander collagen peptide, 0.000001 parts of vitamin D, 0.8 parts of calcium citrate, 8.8 parts of emulsifier (the mass ratio of mono- and di-glycerol fatty acid esters, sodium starch octenylsuccinate and hydroxypropyl methylcellulose is 2:5:1), 1.1 parts of emulsifier modifier (the mass ratio of gum arabic, medium-chain triglycerides and acetylated distarch phosphate is 2:1:1), 25 parts of polydextrose, 25 parts of resistant dextrin, 10 parts of malic acid, 5 parts of citric acid, 35 parts of erythritol and 1.0 part of xanthan gum.
制备方法,包括如下步骤:The preparation method comprises the following steps:
(1)将鱼胶原蛋白、骨胶原蛋白、乳清蛋白和大鲵胶原蛋白肽加入95℃热水中,充分溶解后得到第一混合物,备用;(1) Add fish collagen, bone collagen, whey protein and giant salamander collagen peptide into 95° C. hot water and fully dissolve to obtain a first mixture for later use;
(2)向步骤(1)得到的第一混合物中加入膳食纤维、维生素D、钙、增稠剂和调味剂,充分搅拌至溶液呈均一状,得到第二混合物;(2) adding dietary fiber, vitamin D, calcium, a thickener and a flavoring agent to the first mixture obtained in step (1), and stirring thoroughly until the solution becomes uniform, thereby obtaining a second mixture;
(3)将乳化剂和乳化改性剂加入95℃热水中,搅拌0.5h,使溶解分散均匀,得到溶液;(3) Add the emulsifier and emulsifier modifier into 95°C hot water and stir for 0.5 h to dissolve and disperse evenly to obtain a solution;
(4)将步骤(2)得到的第二混合物和步骤(3)得到的溶液混合,利用高速分散机进行高速剪切,转速为12000rpm/min,剪切时间15min,得到预均质乳液;(5)将预均质乳液进行高压均质处理,均质条件为:均质前进料温度控制在60℃以下,出料温度为70℃以下,均质压力25Mpa,循环均质3次,得到均质乳液,对其进行80℃灭菌30min、降温至35℃以下,即得到所述的奶昔组合物。(4) The second mixture obtained in step (2) and the solution obtained in step (3) are mixed, and high-speed shearing is performed using a high-speed disperser at a rotation speed of 12000 rpm/min and a shearing time of 15 min to obtain a pre-homogenized emulsion; (5) The pre-homogenized emulsion is subjected to high-pressure homogenization treatment, and the homogenization conditions are: the feed temperature before homogenization is controlled below 60°C, the discharge temperature is below 70°C, the homogenization pressure is 25 MPa, and the homogenization is repeated 3 times to obtain a homogenized emulsion, which is sterilized at 80°C for 30 min and cooled to below 35°C to obtain the milkshake composition.
实施例2一种奶昔组合物及其制备方法Example 2 A milkshake composition and preparation method thereof
按重量份数计包括如下组分:The components include the following by weight:
鱼胶原蛋白5份、骨胶原蛋白20份、乳清蛋白0.5份、大鲵胶原蛋白肽0.1份、维生素D 0.000001份、柠檬酸钙0.01份、乳化剂4.8份(单,双甘油脂肪酸酯、辛烯基琥珀酸淀粉钠和羟丙基甲基纤维素的质量比为2:3:1)、乳化改性剂0.4份(阿拉伯胶、中链甘油三酯和乙酰化二淀粉磷酸酯的质量比为3:1:1)、聚葡萄糖50份、抗性糊精50份、苹果酸10份、柠檬酸5份、赤藓糖醇35份、黄原胶0.2份。5 parts of fish collagen, 20 parts of bone collagen, 0.5 parts of whey protein, 0.1 parts of giant salamander collagen peptide, 0.000001 parts of vitamin D, 0.01 parts of calcium citrate, 4.8 parts of emulsifier (the mass ratio of mono- and diglycerol fatty acid esters, sodium starch octenylsuccinate and hydroxypropyl methylcellulose is 2:3:1), 0.4 parts of emulsifier modifier (the mass ratio of gum arabic, medium-chain triglycerides and acetylated distarch phosphate is 3:1:1), 50 parts of polydextrose, 50 parts of resistant dextrin, 10 parts of malic acid, 5 parts of citric acid, 35 parts of erythritol and 0.2 parts of xanthan gum.
制备方法,包括如下步骤:The preparation method comprises the following steps:
(1)将鱼胶原蛋白、骨胶原蛋白、乳清蛋白和大鲵胶原蛋白肽加入90℃热水中,充分溶解后得到第一混合物,备用;(1) Add fish collagen, bone collagen, whey protein and giant salamander collagen peptide into 90° C. hot water and fully dissolve to obtain a first mixture for later use;
(2)向步骤(1)得到的第一混合物中加入膳食纤维、维生素D、钙、增稠剂和调味剂,充分搅拌至溶液呈均一状,得到第二混合物;(2) adding dietary fiber, vitamin D, calcium, a thickener and a flavoring agent to the first mixture obtained in step (1), and stirring thoroughly until the solution becomes uniform, thereby obtaining a second mixture;
(3)将乳化剂和乳化改性剂加入95℃热水中,搅拌1h,使溶解分散均匀,得到溶液;(3) Add the emulsifier and emulsifier modifier into 95°C hot water and stir for 1 hour to dissolve and disperse evenly to obtain a solution;
(4)将步骤(2)得到的第二混合物和步骤(3)得到的溶液混合,利用高速分散机进行高速剪切,转速为15000rpm/min,剪切时间15min,得到预均质乳液;(4) mixing the second mixture obtained in step (2) and the solution obtained in step (3), and performing high-speed shearing using a high-speed disperser at a speed of 15000 rpm/min and a shearing time of 15 min to obtain a pre-homogenized emulsion;
(5)将预均质乳液进行高压均质处理,均质条件为:均质前进料温度控制在60℃以下,出料温度为70℃以下,均质压力80Mpa,循环均质1次,得到均质乳液,对其进行95℃灭菌30min、降温至35℃以下,即得到所述的奶昔组合物。(5) The pre-homogenized emulsion is subjected to high-pressure homogenization treatment. The homogenization conditions are: the feed temperature before homogenization is controlled below 60°C, the discharge temperature is below 70°C, the homogenization pressure is 80 MPa, and the homogenization is circulated once to obtain a homogenized emulsion, which is sterilized at 95°C for 30 min and cooled to below 35°C to obtain the milkshake composition.
实施例3一种奶昔组合物及其制备方法Example 3 A milkshake composition and preparation method thereof
按重量份数计包括如下组分:The components include the following by weight:
鱼胶原蛋白10份、骨胶原蛋白15份、乳清蛋白10份、大鲵胶原蛋白肽0.08份、维生素D 0.000001份、柠檬酸钙0.2份、乳化剂8.1份(单,双甘油脂肪酸酯、辛烯基琥珀酸淀粉钠和羟丙基甲基纤维素的质量比为1:4:1)、乳化改性剂0.9份(阿拉伯胶、中链甘油三酯和乙酰化二淀粉磷酸酯的质量比为1:1:1)、聚葡萄糖30份、抗性糊精30份、苹果酸20份、柠檬酸20份、赤藓糖醇40份、黄原胶0.5份。10 parts of fish collagen, 15 parts of bone collagen, 10 parts of whey protein, 0.08 parts of giant salamander collagen peptide, 0.000001 parts of vitamin D, 0.2 parts of calcium citrate, 8.1 parts of emulsifier (the mass ratio of mono- and di-glycerol fatty acid esters, sodium starch octenylsuccinate and hydroxypropyl methylcellulose is 1:4:1), 0.9 parts of emulsifier modifier (the mass ratio of gum arabic, medium-chain triglycerides and acetylated distarch phosphate is 1:1:1), 30 parts of polydextrose, 30 parts of resistant dextrin, 20 parts of malic acid, 20 parts of citric acid, 40 parts of erythritol and 0.5 parts of xanthan gum.
制备方法,包括如下步骤:The preparation method comprises the following steps:
(1)将鱼胶原蛋白、骨胶原蛋白、乳清蛋白和大鲵胶原蛋白肽加入90℃热水中,充分溶解后得到第一混合物,备用;(1) Add fish collagen, bone collagen, whey protein and giant salamander collagen peptide into 90° C. hot water and fully dissolve to obtain a first mixture for later use;
(2)向步骤(1)得到的第一混合物中加入膳食纤维、维生素D、钙、增稠剂和调味剂充分搅拌至溶液呈均一状,得到第二混合物;(2) adding dietary fiber, vitamin D, calcium, a thickener and a flavoring agent to the first mixture obtained in step (1) and stirring thoroughly until the solution becomes uniform to obtain a second mixture;
(3)将乳化剂和乳化改性剂加入90℃热水中,搅拌2h,使溶解分散均匀,得到溶液;(3) Add the emulsifier and emulsifier modifier into 90°C hot water and stir for 2 hours to make them evenly dissolved and dispersed to obtain a solution;
(4)将步骤(2)得到的第二混合物和步骤(3)得到的溶液混合,利用高速分散机进行高速剪切,转速为12000rpm/min,剪切时间20min,得到预均质乳液;(4) mixing the second mixture obtained in step (2) and the solution obtained in step (3), and performing high-speed shearing using a high-speed disperser at a speed of 12000 rpm/min and a shearing time of 20 min to obtain a pre-homogenized emulsion;
(5)将预均质乳液进行高压均质处理,均质条件为:均质前进料温度控制在60℃以下,出料温度为70℃以下,均质压力25Mpa,循环均质2次,得到均质乳液,对其进行95℃灭菌30min、降温至35℃以下,即得到所述的奶昔组合物。(5) The pre-homogenized emulsion is subjected to high-pressure homogenization treatment. The homogenization conditions are: the feed temperature before homogenization is controlled below 60°C, the discharge temperature is below 70°C, the homogenization pressure is 25 MPa, and the homogenization is repeated twice to obtain a homogenized emulsion, which is sterilized at 95°C for 30 min and cooled to below 35°C to obtain the milkshake composition.
实施例4一种奶昔组合物及其制备方法Example 4 A milkshake composition and preparation method thereof
按重量份数计包括如下组分:The components include the following by weight:
鱼胶原蛋白30份、骨胶原蛋白10份、乳清蛋白12份、大鲵胶原蛋白肽0.08份、维生素D 0.000001份、柠檬酸钙0.3份、乳化剂7份(单,双甘油脂肪酸酯、辛烯基琥珀酸淀粉钠和羟丙基甲基纤维素的质量比为1:3:1)、乳化改性剂0.7份(阿拉伯胶、中链甘油三酯和乙酰化二淀粉磷酸酯的质量比为2:1:1)、聚葡萄糖40份、抗性糊精40份、苹果酸20份、柠檬酸20份、赤藓糖醇40份、黄原胶1.0份。30 parts of fish collagen, 10 parts of bone collagen, 12 parts of whey protein, 0.08 parts of giant salamander collagen peptide, 0.000001 parts of vitamin D, 0.3 parts of calcium citrate, 7 parts of emulsifier (the mass ratio of mono- and di-glycerol fatty acid esters, sodium starch octenylsuccinate and hydroxypropyl methylcellulose is 1:3:1), 0.7 parts of emulsifier modifier (the mass ratio of gum arabic, medium-chain triglycerides and acetylated distarch phosphate is 2:1:1), 40 parts of polydextrose, 40 parts of resistant dextrin, 20 parts of malic acid, 20 parts of citric acid, 40 parts of erythritol and 1.0 part of xanthan gum.
制备方法,包括如下步骤:The preparation method comprises the following steps:
(1)将鱼胶原蛋白、骨胶原蛋白、乳清蛋白和大鲵胶原蛋白肽加入90℃热水中,充分溶解后得到第一混合物,备用;(1) Add fish collagen, bone collagen, whey protein and giant salamander collagen peptide into 90° C. hot water and fully dissolve to obtain a first mixture for later use;
(2)向步骤(1)得到的第一混合物中加入膳食纤维、维生素D、钙、增稠剂和调味剂,充分搅拌至溶液呈均一状,得到第二混合物;(2) adding dietary fiber, vitamin D, calcium, a thickener and a flavoring agent to the first mixture obtained in step (1), and stirring thoroughly until the solution becomes uniform, thereby obtaining a second mixture;
(3)将乳化剂和乳化改性剂加入95℃热水中,搅拌1h,使溶解分散均匀,得到溶液;(3) Add the emulsifier and emulsifier modifier into 95°C hot water and stir for 1 hour to dissolve and disperse evenly to obtain a solution;
(4)将步骤(2)得到的第二混合物和步骤(3)得到的溶液混合,利用高速分散机进行高速剪切,转速为12000rpm/min,剪切时间20min,得到预均质乳液;(4) mixing the second mixture obtained in step (2) and the solution obtained in step (3), and performing high-speed shearing using a high-speed disperser at a speed of 12000 rpm/min and a shearing time of 20 min to obtain a pre-homogenized emulsion;
(5)将预均质乳液进行高压均质处理,均质条件为:均质前进料温度控制在60℃以下,出料温度为70℃以下,均质压力100Mpa,循环均质2次,得到均质乳液对其进行95℃灭菌30min、降温至35℃以下,即得到所述的奶昔组合物。(5) The pre-homogenized emulsion is subjected to high-pressure homogenization treatment. The homogenization conditions are: the feed temperature before homogenization is controlled below 60°C, the discharge temperature is below 70°C, the homogenization pressure is 100 MPa, and the homogenization is repeated twice to obtain a homogenized emulsion, which is sterilized at 95°C for 30 min and cooled to below 35°C to obtain the milkshake composition.
对比例1Comparative Example 1
与实施例4的区别在于:不添加乳化改性剂,乳化剂的总量为7.7份,其他步骤和操作与实施例4相同。The difference from Example 4 is that no emulsifying modifier is added, the total amount of the emulsifier is 7.7 parts, and the other steps and operations are the same as those of Example 4.
对比例2Comparative Example 2
与实施例4的区别在于:乳化改性剂仅为阿拉伯胶和乙酰化二淀粉磷酸酯的质量比为1:3,乳化改性剂的总质量与实施例4相同,其他步骤和操作与实施例4相同。The difference from Example 4 is that the emulsifying modifier is only gum arabic and acetylated distarch phosphate in a mass ratio of 1:3, the total mass of the emulsifying modifier is the same as that in Example 4, and the other steps and operations are the same as those in Example 4.
对比例3Comparative Example 3
与实施例4的区别在于:乳化剂与乳化改性剂的质量比为4:1,乳化剂与乳化改性剂的总质量与实施例4相同,即乳化剂6.16份,乳化改性剂1.54份,其他步骤和操作与实施例4相同。The difference from Example 4 is that the mass ratio of emulsifier to emulsification modifier is 4:1, the total mass of emulsifier and emulsification modifier is the same as that in Example 4, i.e., 6.16 parts of emulsifier and 1.54 parts of emulsification modifier, and the other steps and operations are the same as those in Example 4.
对比例4Comparative Example 4
与实施例4的区别在于:乳化剂与乳化改性剂的质量比为1:4,乳化剂与乳化改性剂的总质量与实施例4相同,即乳化剂1.54份,乳化改性剂6.16份,其他步骤和操作与实施例4相同。The difference from Example 4 is that the mass ratio of emulsifier to emulsification modifier is 1:4, the total mass of emulsifier and emulsification modifier is the same as that in Example 4, i.e., 1.54 parts of emulsifier and 6.16 parts of emulsification modifier, and the other steps and operations are the same as those in Example 4.
对比例5Comparative Example 5
与实施例4的区别在于:步骤(4)中利用高速分散机进行高速剪切,转速为10000rpm/min,步骤(5)中的均质压力为15Mpa,其他步骤和操作与实施例4相同。The difference from Example 4 is that in step (4), a high-speed disperser is used for high-speed shearing at a rotation speed of 10000 rpm/min, and the homogenization pressure in step (5) is 15 MPa. The other steps and operations are the same as those in Example 4.
对比例6Comparative Example 6
与实施例4的区别在于:步骤(4)中利用高速分散机进行高速剪切,转速为20000rpm/min,步骤(5)中的均质压力为150Mpa,其他步骤和操作与实施例4相同。The difference from Example 4 is that in step (4), a high-speed disperser is used for high-speed shearing at a rotation speed of 20,000 rpm/min, and the homogenization pressure in step (5) is 150 MPa. The other steps and operations are the same as those in Example 4.
效果实验Effect experiment
1、产品稳定性测试1. Product stability test
取50ml实施例1-4以及对比例1-6制备的样品进行离心处理,通过沉淀量来对比稳定性差异。离心参数为6000rpm/min、15min,离心完成后倒置3min去除上清液,称量得到沉淀物重量,每组进行3次,取平均值;检测结果见下表1。50 ml of the samples prepared in Examples 1-4 and Comparative Examples 1-6 were centrifuged to compare the stability differences by the amount of precipitation. The centrifugation parameters were 6000 rpm/min, 15 min. After the centrifugation was completed, the supernatant was removed by inversion for 3 min, and the weight of the precipitate was weighed. Each group was subjected to 3 times and the average value was taken. The test results are shown in Table 1 below.
表1Table 1
根据上表1的检测数据可知,复合乳化剂对纳米乳液的稳定性有明显的影响;实施例1-4中采用乳化剂和乳化改性剂组合得到的纳米乳液稳定性更好,尤其是实施例4中以单,双甘油脂肪酸酯、辛烯基琥珀酸淀粉钠和羟丙基甲基纤维素的混合物作为乳化剂,控制三者的质量比为1:3:1,并以阿拉伯胶、中链甘油三酯和乙酰化二淀粉磷酸酯的混合物作为乳化改性剂,并控制三者的质量比为2:1:1;得到的纳米乳液的稳定性最高;对比例1-2中改变乳化改性剂的种类或配比会明显影响纳米乳液的稳定性;对比例3-4改变乳化剂与乳化改性剂的质量比,对比5-6改变剪切转速以及均质压力均会在一定程度纳米乳液的稳定性。According to the test data in Table 1 above, the composite emulsifier has a significant effect on the stability of the nanoemulsion; the nanoemulsion obtained by combining an emulsifier and an emulsification modifier in Examples 1-4 has better stability, especially in Example 4, a mixture of mono- and diglycerol fatty acid esters, sodium starch octenyl succinate and hydroxypropyl methylcellulose is used as an emulsifier, and the mass ratio of the three is controlled to be 1:3:1, and a mixture of gum arabic, medium-chain triglycerides and acetylated distarch phosphate is used as an emulsification modifier, and the mass ratio of the three is controlled to be 2:1:1; the obtained nanoemulsion has the highest stability; in Comparative Examples 1-2, changing the type or ratio of the emulsification modifier will significantly affect the stability of the nanoemulsion; Comparative Examples 3-4 change the mass ratio of the emulsifier to the emulsification modifier, and Comparative Examples 5-6 change the shear speed and the homogenization pressure will all affect the stability of the nanoemulsion to a certain extent.
2、蛋白的跨膜转运测试2. Protein transmembrane transport test
本实验所用的Caco-2细胞为对数生长期的细胞,所用的Caco-2细胞为35-45 代。取Caco-2细胞制成单层模型,通过细胞细胞毒性实验确认最高转运质量浓度为0.375mg/ml。取出已建立好的Caco-2细胞单层模型,设计单向转运实验。在转运实验中,通过测试不同时间点接受侧吸收的药量(累积转运量)计算表观渗透系数P,来分析转运的效率,测试时间为180min。The Caco-2 cells used in this experiment are cells in the logarithmic growth phase, and the Caco-2 cells used are 35-45 generations. Caco-2 cells were made into a monolayer model, and the highest transport mass concentration was confirmed to be 0.375 mg/ml through cell cytotoxicity experiments. The established Caco-2 cell monolayer model was taken out and a unidirectional transport experiment was designed. In the transport experiment, the apparent permeability coefficient P was calculated by testing the amount of drug absorbed by the receiving side at different time points (cumulative transport amount) to analyze the efficiency of transport, and the test time was 180 minutes.
P=ΔQ÷(Δt×A× p0),P = ΔQ ÷ (Δt × A × p0),
ΔQ为时间Δt/s内的累积转运量/mg;A为聚碳酸脂膜的面积(5.8 cm2);ρ0为初始质量浓度/(mg/mL),初始质量浓度为0.375mg/ml。ΔQ is the cumulative transport amount/mg within the time Δt/s; A is the area of the polycarbonate membrane (5.8 cm 2 ); ρ0 is the initial mass concentration/(mg/mL), and the initial mass concentration is 0.375 mg/ml.
检测结果见下表2。The test results are shown in Table 2 below.
表2Table 2
根据上表2的检测数据可知,复合乳化剂对纳米乳液的蛋白的跨膜转运能力有明显的影响;实施例1-4中采用乳化剂和乳化改性剂组合得到的纳米乳液蛋白的跨膜转运能力更好,累计转运量均值可达到170ug以上,尤其是实施例4中以单,双甘油脂肪酸酯、辛烯基琥珀酸淀粉钠和羟丙基甲基纤维素的混合物作为乳化剂,控制三者的质量比为1:3:1,并以阿拉伯胶、中链甘油三酯和乙酰化二淀粉磷酸酯的混合物作为乳化改性剂,并控制三者的质量比为2:1:1;得到的纳米乳液的跨膜转运能力最好,累计转运量均值可达到332.20ug;对比例1-2中改变乳化改性剂的种类或配比会明显影响纳米乳液的跨膜转运能力;对比例3-4改变乳化剂与乳化改性剂的质量比,对比5-6改变剪切转速以及均质压力均会在一定程度纳米乳液的跨膜转运能力。According to the test data in Table 2 above, the composite emulsifier has a significant effect on the transmembrane transport ability of the protein in the nanoemulsion; the nanoemulsion protein transmembrane transport ability obtained by combining the emulsifier and the emulsifier modifier in Examples 1-4 is better, and the cumulative transport amount average can reach more than 170ug, especially in Example 4, a mixture of mono- and di-glycerol fatty acid esters, sodium octenyl succinate starch and hydroxypropyl methylcellulose is used as an emulsifier, and the mass ratio of the three is controlled to be 1:3:1, and gum arabic and medium-chain glycerol are used as the emulsifier. A mixture of triester and acetylated distarch phosphate is used as an emulsifying modifier, and the mass ratio of the three is controlled to be 2:1:1; the obtained nanoemulsion has the best transmembrane transport ability, and the average cumulative transport amount can reach 332.20ug; in comparative examples 1-2, changing the type or ratio of the emulsifying modifier will significantly affect the transmembrane transport ability of the nanoemulsion; in comparative examples 3-4, changing the mass ratio of the emulsifier to the emulsifying modifier, and in comparative examples 5-6, changing the shear speed and the homogenization pressure will affect the transmembrane transport ability of the nanoemulsion to a certain extent.
最后应当说明的是,以上内容仅用以说明本发明的技术方案,而非对本发明保护范围的限制,本领域的普通技术人员对本发明的技术方案进行的简单修改或者等同替换,均不脱离本发明技术方案的实质和范围。Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410964180.9A CN118489901B (en) | 2024-07-18 | 2024-07-18 | Nanometer ultramicro emulsification process and product prepared by adopting same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410964180.9A CN118489901B (en) | 2024-07-18 | 2024-07-18 | Nanometer ultramicro emulsification process and product prepared by adopting same |
Publications (2)
Publication Number | Publication Date |
---|---|
CN118489901A true CN118489901A (en) | 2024-08-16 |
CN118489901B CN118489901B (en) | 2024-11-08 |
Family
ID=92240094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410964180.9A Active CN118489901B (en) | 2024-07-18 | 2024-07-18 | Nanometer ultramicro emulsification process and product prepared by adopting same |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118489901B (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013171100A1 (en) * | 2012-05-16 | 2013-11-21 | Joachim Hans | Polyhydroxylated pentacyclic triterpene acids as hmg-coa reductase inhibitors |
CN104054849A (en) * | 2014-05-21 | 2014-09-24 | 上海英莱腾医药研究有限公司 | High-content medium chain triglyceride powdered oil and preparation method thereof |
CN107495343A (en) * | 2017-09-08 | 2017-12-22 | 天津活力达生物科技有限公司 | A kind of generation meal milk shake and preparation method thereof |
US20190085034A1 (en) * | 2016-03-16 | 2019-03-21 | Tarveda Therapeutics, Inc. | Antibody mimic conjugates and particles |
CN110973644A (en) * | 2019-12-16 | 2020-04-10 | 广州白云山汉方现代药业有限公司 | Casein and whey protein compounded nutritional suspension and preparation thereof |
AU2020102945A4 (en) * | 2020-10-21 | 2020-12-17 | Beijing Health Information Medical Technology Inc. | Compound oil microcapsule with reasonable fatty acid proportion and high stability and its preparation method thereof |
CN112293560A (en) * | 2019-07-25 | 2021-02-02 | 中粮集团有限公司 | Instant soybean protein composition and preparation method thereof |
CN117050292A (en) * | 2023-08-31 | 2023-11-14 | 浙江赛本达新材料科技有限公司 | Emulsion modifier polyether and preparation method thereof |
CN117562257A (en) * | 2024-01-15 | 2024-02-20 | 北京衡美金叶营养健康科技有限公司 | High-fat low-carbon food composition and preparation method thereof |
-
2024
- 2024-07-18 CN CN202410964180.9A patent/CN118489901B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013171100A1 (en) * | 2012-05-16 | 2013-11-21 | Joachim Hans | Polyhydroxylated pentacyclic triterpene acids as hmg-coa reductase inhibitors |
CN104054849A (en) * | 2014-05-21 | 2014-09-24 | 上海英莱腾医药研究有限公司 | High-content medium chain triglyceride powdered oil and preparation method thereof |
US20190085034A1 (en) * | 2016-03-16 | 2019-03-21 | Tarveda Therapeutics, Inc. | Antibody mimic conjugates and particles |
CN107495343A (en) * | 2017-09-08 | 2017-12-22 | 天津活力达生物科技有限公司 | A kind of generation meal milk shake and preparation method thereof |
CN112293560A (en) * | 2019-07-25 | 2021-02-02 | 中粮集团有限公司 | Instant soybean protein composition and preparation method thereof |
CN110973644A (en) * | 2019-12-16 | 2020-04-10 | 广州白云山汉方现代药业有限公司 | Casein and whey protein compounded nutritional suspension and preparation thereof |
AU2020102945A4 (en) * | 2020-10-21 | 2020-12-17 | Beijing Health Information Medical Technology Inc. | Compound oil microcapsule with reasonable fatty acid proportion and high stability and its preparation method thereof |
CN117050292A (en) * | 2023-08-31 | 2023-11-14 | 浙江赛本达新材料科技有限公司 | Emulsion modifier polyether and preparation method thereof |
CN117562257A (en) * | 2024-01-15 | 2024-02-20 | 北京衡美金叶营养健康科技有限公司 | High-fat low-carbon food composition and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
REINER, SJ: "A Comparison of the Stability of Beverage Cloud Emulsions Formulated with Different Gum Acacia- and Starch-Based Emulsifiers", JOURNAL OF FOOD SCIENCE, vol. 75, no. 5, 31 December 2010 (2010-12-31), pages 236 - 246 * |
魏振承;徐志宏;池建伟;张名位;张雁;李健雄;唐小俊;张瑞芬;: "短肽免疫增强型临床营养乳剂的配方和制备工艺研究", 中国粮油学报, no. 07, 25 July 2009 (2009-07-25), pages 120 - 123 * |
Also Published As
Publication number | Publication date |
---|---|
CN118489901B (en) | 2024-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2489566C (en) | Gel beverage composition | |
EP2424386B1 (en) | Pea-based protein mixture and use thereof in a liquid nutritional composition suitable for enteral feeding | |
EP2651249B1 (en) | Method for making whey protein composition with a reduced astringency | |
TW200412861A (en) | Gel-form composition for supplying protein and calcium | |
JP5373227B1 (en) | Method for producing nutritional composition | |
CN1284838A (en) | Gelled foods and process for producing the same | |
CN104187711B (en) | A kind of whole albumen and small peptide compound clinical patient spy's meals nutrition emulsion and preparation method thereof | |
EP2954787A1 (en) | Liquid enteral nutritional composition with a low monovalent metal ion content | |
JPS6236645B2 (en) | ||
KR102291249B1 (en) | Food composition for protein supplement containing chocolate flavor | |
CN110353145A (en) | A kind of multi-component nutrients solid beverage and preparation method thereof | |
EP4223137A1 (en) | Whey protein composition, and preparation method therefor and use thereof | |
JP2007532534A (en) | Concentrated liquid preparation | |
CN109152402A (en) | Heat sterilization high protein enteral composition with the lactalbumin comprising whey protein micelles and Casein in Milk | |
JP5384333B2 (en) | Liquid nutritional composition containing whey protein at high concentration and method for producing the same | |
CN108576524A (en) | A kind of peracidity sport nutrition liquid and its preparation process | |
CN104431280A (en) | Soybean ice cream powder, soybean ice cream and preparation method of soybean ice cream | |
CN115399449A (en) | Preparation method of bone nutrition snowflake tablets | |
JPH10155432A (en) | New pectin and emulsified liquid containing the same | |
CN1698448A (en) | Polypeptide almond milk and preparation method thereof | |
CN118489901A (en) | Nano-ultra-micro emulsification process and products prepared by the process | |
CN110584120A (en) | Bone health composition | |
CN106417616A (en) | Milk-fruit grain products and preparation method thereof | |
CN112806573A (en) | Ketogenic dietary composition, ketogenic protein bar and preparation method thereof | |
CN113995127A (en) | Full-nutrition formula food and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |